Lates News

According to a research report released by Huaan Securities on May 6th, Biolight (002880.SZ) has been given a buy rating. The reasons for this rating mainly include: 1) Double growth in revenue and profit by 2024; 2) Significant cost control effects, leading to improved profitability; 3) Steady growth in main business, excellent performance of core products, and continuous increase in plasma collection volume; 4) Further enrichment of product lines, improving plasma utilization rate; 5) Steady growth in plasma collection volume. (Daily Economic News)